Thomas Powles

36.5k citations

338 papers · 10.6k indexed · 11 hit papers · h-index 49

Impact in

Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Surgery top 0.2%
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies

Papers in

Oncology 207
- Cancer Immunotherapy and Biomarkers 165
Surgery 265
- Bladder and Urothelial Cancer Treatments 244
- Urinary and Genital Oncology Studies 125
- Esophageal Cancer Research and Treatment 20
- Testicular diseases and treatments 17

Co-authors: Yohann Loriot Nicholas J. Vogelzang Daniel S. Chen Joaquim Bellmunt Daniel P. Petrylak Priti S. Hegde Gregg Fine Xiaodong Shen
Journals: Journal of Clinical Oncology (131 papers)Annals of Oncology (52 papers)European Urology (20 papers)British Journal of Urology (7 papers)European Urology Oncology (7 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Thomas Powles

315 papers receiving 10.5k citations

Hit Papers

11 papers align trajectories log scale

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update 2025 · 18 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 European Urology
2024 The Lancet
2023 Annals of Oncology
2023 Journal of Clinical Oncology
2023 Immunity
2023 Annals of Oncology
2022 Nature Medicine
2022 Annals of Oncology
2021 New England Journal of Medicine
2016 Journal of Clinical Oncology
2014 Nature

Peers

Countries citing papers authored by Thomas Powles

Since Specialization

Citations

This map shows the geographic impact of Thomas Powles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Powles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Powles more than expected).

Fields of papers citing papers by Thomas Powles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Powles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Powles. The network helps show where Thomas Powles may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas Powles, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Powles Line = papers co-authored together Thomas Powles links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	LBA108 Durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Final analysis of the phase III, open-label, randomised POTOMAC trial Annals of Oncology ·Dam Binoyargha, Juan Palou, Andreas Bieberstein, M Krawczyński, J. D'ans, 堯彦瀬名, 上野桂子, James J. Zhang, Lieven Goeman, Eva Hellmis, Thomas Powles, F Miklos, P. Vasey, P. Bigot, Yves Fradet, 乙彦加賀, Srinidhi Desikan, A. Lazzaro, E. Keppler, Keiji Kimura	2025	0
2	1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC) Annals of Oncology ·Thomas Powles, Michiel S. van der Heijden, Shilpa Gupta, Begoña P. Valderrama, R W JACKSON, A.D. Mikhailin, Eiji Kikuchi, Jean Hoffman‐Censits, J.P. Maroto Rey, Christof Vulsteke, Gopa Iyer, Umang Swami, Sang Joon Shin, Alejo Rodríguez‐Vida, Michał Woźniak, Blanca Homet Moreno, Jie Lu, Changjun Yu, Leah J. Hogdal, Yohann Loriot	2024	13
3	269O Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Annals of Oncology ·Eiji Kikuchi, Michiel S. van der Heijden, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Su‐Jin Shin, S. John Wort, J. Guo, Pongwut Danchaivijitr, Z. Strezova, Eric Snow Mr., Wen‐Pin Su, Kikuko HAMAGUCHI, Woo Kyun Bae, Alvin Wong, Jiaying Lu, Xuesong Yu, J.-L. Cui, Abhishek Bavle, Thomas Powles	2024	1
4	REAL-WORLD ELIGIBILITY AND UTILIZATION OF AVELUMAB MAINTENANCE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA Urologic Oncology Seminars and Original Investigations ·Alicia K. Morgans, Guru Sonpavde, Deepti Ahluwalia, Phoebe Wright, Zsolt Hepp, Candice Willmon, Nancy N. Chang, 文伸岡田, 一夫笹山, Thomas Powles	2024	0
5	Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001). Journal of Clinical Oncology ·Matt D. Galsky, Enrique Grande, Andrea Necchi, Alexandra Drakaki, Yohann Loriot, Sonia Franco, 史佳河原, Wei Zhang, Thomas Powles	2024	0
6	Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology ·G Dobrolubov, F. Fujiwara, Jeeban Paul Das, Thomas Powles, Dean F. Bajorin, Ritesh R. Kotecha, H. GURSKY, Han Xiao, Emily Feld, Deaglan Joseph McHugh, Niamh M. Keegan, Samuel A. Funt, Neil J. Shah, Gopa Iyer, David H. Aggen, Min Yuen Teo, Irina Ostrovnaya, Jonathan E. Rosenberg	2024	1
7	Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. Journal of Clinical Oncology ·Matt D. Galsky, Guru Sonpavde, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, Michiel Simon Van Der Heijden	2024	11
8	Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden. Journal of Clinical Oncology ·Joaquim Bellmunt, Thomas Powles, Se Hoon Park, Éric Voog, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Cora N. Sternberg, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Miguel Á. Climent Durán, 美紀江渡, 直樹高林, DEEP HATHI, Petros Grivas, Shilpa Gupta	2024	3
9	Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39. Journal of Clinical Oncology ·Michiel Simon Van Der Heijden, Shilpa Gupta, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Gopa Iyer, Yohann Loriot, Nancy A. Dawson, Jean Hoffman‐Censits, Nataliya Mar, Srikala S. Sridhar, Qi Peng, Sang Joon Shin, Evan Y. Yu, Ignacio Durán, Xi Xi, Xuesong Yu, Aditya Shetty, Abhishek Bavle, Thomas Powles	2024	3
10	Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma European Urology ·Thomas Powles, Zoe J. Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Himanshu Sethi, Alexey Aleshin, Yi Shi, Nicole N. Davarpanah, Corey Carter, Joaquim Bellmunt, Sanjeev Mariathasan	2023	61
11	LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial Annals of Oncology ·Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, B.H. Viana Montanera, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Joe Young, X. Dong, Zhisong He, Begoña P. Valderrama, 立教大学フランス語フランス文学研究室, Adekunle Sanyaolu, Daniela Purcea, Federico Nasroulah, Matt D. Galsky	2023	9
12	1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC) Annals of Oncology ·DNA問題研究会, Kosuke Takemura, Devon J. Boyne, Matthew T. Warkentin, Darren R. Brenner, イチロウイノウエ, J. Connor Wells, Chris Labaki, Bradley A. McGregor, M. Suk, Luís Meza, Sumanta K. Pal, Benoit Beuselinck, Rana R. McKay, Bernadett Szabados, Thomas Powles, Takeshi Yuasa, Leopold Ludwig, Toni K. Choueiri, E Crooks	2023	2
13	2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC) Annals of Oncology ·Andrea Necchi, James W.F. Catto, Thomas Powles, Félix Guerrero‐Ramos, Giuseppe Simone, Neal D. Shore, Jorge Salinas, Axel S. Merseburger, M. Roumiguié, Hiroshi Kitamura, David Morris, Qiang Wei, Fernando Korkes, S.M.Kurt Lee, Sheng Jin, Apriandirizkina Rangga Wastu, Constance Hammond, Hussein Sweiti, Robert A. Somer, Sam S. Chang	2023	6
14	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Syed A. Hussain, J.F. Lester, Richard A. Jackson, Heather Goodson, Ph. Ridereau, Anthony Elliott, Simon J. Crabb, Robert Huddart, Naveen Vasudev, Alison Birtle, Jane Worlding, Nicholas D. James, Omi Parikh, Maria Vilarino-Varela, Roberto Alonzi, Mark Linch, Irbaz Bin Riaz, James W.F. Catto, Thomas Powles, Robert J. Jones	2022	20
15	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Clinical Cancer Research ·Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles	2021	54
16	Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19 Journal of Cancer Education ·Iulia-Elena Filipescu, Huafang Yan, В.С. Михейчик, В. В. Чорна, Russell C. Bogue, Abbas F. M. Alrubayee, ვ. ჩიხლაძე, Shanthini Mary Crusz, Thakur Dhakal, Bernadett Szabados, Paula Wells, Ekaterini Boleti, Thomas Powles	2021	5
17	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer Cancer ·Alberto Martini, Rachel Jia, Bart S. Ferket, Nikhil Waingankar, Elizabeth R. Plimack, Simon J. Crabb, Lauren C. Harshman, Evan Y. Yu, Thomas Powles, Jonathan E. Rosenberg, Sumanta K. Pal, Ulka N. Vaishampayan, Andrea Necchi, Peter Wiklund, Reza Mehrazin, Madhu Mazumdar, John P. Sfakianos, Matthew D. Galsky	2019	26
18	HLA-B 57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer Clinical Cancer Research* ·Chun‐Fang Xu, Toby Johnson, Xiaojing Wang, Chris Carpenter, Alan P. Graves, Liling Warren, Zhengyu Xue, Karen S. King, Dana J. Fraser, E. Strømme, Linda P. Briley, Ionel Mitrica, Colin F. Spraggs, Matthew R. Nelson, Hiroomi Tada, Andreas du Bois, Thomas Powles, Neil Kaplowitz, Lini Pandite	2015	70
19	A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP Molecular Cancer Therapeutics ·Erik Wengström, Essam Ghazaly, Tyrone Weeks, E. García Samper, Simon Joel, Thomas Powles	2010	32
20	Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection Journal of Clinical Oncology ·Thomas Powles, David Robinson, Justin Stebbing, Jonathan Shamash, Mark Nelson, Brian Gazzard, Françoise Dubosson, Henrik Møller, Mark Bower	2008	269

About Thomas Powles

Thomas Powles is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Cancer Research and Biotechnology, having authored 338 papers that have together received 10.6k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (244 papers), Cancer Immunotherapy and Biomarkers (165 papers), Urinary and Genital Oncology Studies (125 papers), Renal cell carcinoma treatment (62 papers), Multiple and Secondary Primary Cancers (36 papers), Cancer Genomics and Diagnostics (23 papers), Esophageal Cancer Research and Treatment (20 papers) and Testicular diseases and treatments (17 papers). The work is most often cited by research in Oncology (5.9k citations), Surgery (5.3k citations), Pulmonary and Respiratory Medicine (2.9k citations), Immunology (1.9k citations) and Cancer Research (1.0k citations). Thomas Powles has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Yohann Loriot, Nicholas J. Vogelzang, Daniel S. Chen, Joaquim Bellmunt, Daniel P. Petrylak, Priti S. Hegde, Gregg Fine, Xiaodong Shen, Howard A. Burris and Fadi S. Braiteh. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Urology, British Journal of Urology and European Urology Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact